The variable weight effect of exenatide treatment.
نویسنده
چکیده
Corresponding Author: Allen B. King, M.D., Diabetes Care Center, 1260 S. Main, Salinas, CA 93901; email address [email protected] Exenatide, a glucagon-like peptide-1 agonist, has enjoyed popularity with treating physicians because it dramatically reduces postmeal glucose (at least early in diabetes), increases β cell mass (at least in vitro and in rodents), and reduces weight. Some authors report the weight loss as continuous over a 3.5-year observational period.1 This has not been my experience.
منابع مشابه
Exenatide in obesity with accelerated gastric emptying: a randomized, pharmacodynamics study
Obesity is associated with differences in satiety, gastric emptying (GE), gastric volume, and psychological traits. Exenatide, a short-acting glucagon-like peptide 1 (GLP-1) receptor agonist, is associated with variable weight loss. We compared the effects of exenatide, 5 μg, and placebo SQ, twice daily for 30 days on GE of solids and liquids (scintigraphy), satiety (ad libitum buffet meal), sa...
متن کاملShort-Term Exenatide Treatment Leads to Significant Weight Loss in a Subset of Obese Women Without Diabetes
OBJECTIVE To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women. RESEARCH DESIGN AND METHODS Forty-one obese women (aged 48 ± 11 years and BMI 33.1 ± 4.1 kg/m(2)) participated in a 35-week randomized, double-blind, placebo-controlled, crossover study, including two 16-week treatment...
متن کاملEffects of Exenatide in a Morbidly Obese Patient with Type 2 Diabetes
INTRODUCTION The effect of exenatide in weight loss has been reported. Presented here is a case of a morbidly obese patient with type 2 diabetes using exenatide who dramatically lost her body weight in a year and experienced improved glycemic control. CASE REPORT Exenatide therapy was initiated for a 59-year-old morbidly obese Japanese woman with type 2 diabetes. To examine the effects of the...
متن کاملExenatide Affects Circulating Cardiovascular Risk Biomarkers Independently of Changes in Body Composition
OBJECTIVE To study the effect of exenatide on body composition and circulating cardiovascular risk biomarkers. RESEARCH DESIGN AND METHODS Metformin-treated patients with type 2 diabetes (N = 69) were randomized to exenatide or insulin glargine and treated for 1 year. Body composition was evaluated by dual-energy X-ray absorptiometry. Additionally, body weight, waist circumference, and cardio...
متن کاملExenatide once-weekly injection for the treatment of type 2 diabetes in Chinese patients: current perspectives
Glucagon-like peptide-1 (GLP-1) analogs, such as exenatide, have played an important role as antidiabetic medications in the treatment of type 2 diabetes (T2DM). Like most other hypoglycemic agents, exenatide has a number of actions, including lowering blood glucose, promoting weight loss, improving insulin resistance, and protecting islet β-cells. Although GLP-1 analogs, combined with other an...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Journal of diabetes science and technology
دوره 2 3 شماره
صفحات -
تاریخ انتشار 2008